Previous 10 | Next 10 |
2023-05-22 17:30:42 ET Gainers: Movella Holdings ( MVLA ) +14% . Trevi Therapeutics ( TRVI ) +5% . QUALCOMM ( QCOM ) +5% . Galera Therapeutics ( GRTX ) +4% . LivePerson ( LPSN ) +4% . Losers: Guardant Health (...
2023-05-15 18:41:06 ET Biora Therapeutics, Inc. (BIOR) Q1 2023 Earnings Conference Call May 15, 2023, 16:30 ET Company Participants Kristy Grabowski - IR Aditya Mohanty - CEO & Director Eric d'Esparbes - EVP & CFO Conference Call Participants ...
2023-05-15 16:16:15 ET Biora Therapeutics press release ( NASDAQ: BIOR ): Q1 GAAP EPS of -$1.59 beats by $0.16 . The company successfully raised $12.9 million in gross proceeds from its ATM program during the first quarter, leading to a stable cash balance of $30.5 mil...
Completed execution of toxicology study for NaviCap™ BT-600 program with no adverse events indicated in preliminary data; on track to file IND in Q3 2023 Preclinical testing for the BioJet™ platform is advancing both internally and with pharma collaborator’s molecul...
SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report first quarter ended March 31, 2023 financial results on Monday, May 15, 2023 after the close of financial mar...
SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the appointment of Ariella Kelman, MD, as Chief Medical Officer. Dr. Kelman has a proven track record of leading global biopharma...
SAN DIEGO, April 20, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will participate in IBD Innovate: Product Development for Crohn’s & Colitis , an event hosted by the Cro...
2023-03-30 22:21:06 ET Biora Therapeutics, Inc. (BIOR) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Chuck Padala – Managing Director-LifeSci Advisors Adi Mohanty – Chief Executive Officer Eric d'Esparbes – C...
2023-03-30 16:17:29 ET Biora Therapeutics press release ( NASDAQ: BIOR ): Q4 GAAP EPS of -$1.64 misses by $0.19 . Revenue of $0.14M (-68.2% Y/Y) beats by $0.08M . For further details see: Biora Therapeutics GAAP EPS of -$1.64 misses by $0.19, revenue of $...
Biora initiating preclinical testing with pharma collaborator’s molecule following recent data exceeding the company’s target bioavailability levels for systemic therapeutics platform No adverse events indicated in 14-day tox study for targeted therapeutics program ...
News, Short Squeeze, Breakout and More Instantly...
Biora Therapeutics Inc. Company Name:
BIOR Stock Symbol:
NASDAQ Market:
Biora Therapeutics Inc. Website:
Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired Data modeling suggests tofacitinib tissue concentrations greater than IC90 through at least 16 hours after dosing SAN DIEGO, July 18...
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced further details on its virtual event to be held on Wednesday, July 17, 2024. The event will feature Bruce Sands, MD, MS (Icahn School of ...
Drug-device combination leverages Biora’s NaviCap ™ platform to deliver tofacitinib directly to colonic tissue as a potential treatment for ulcerative colitis BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ab...